Morphological and functional platelet abnormalities in Berkeley sickle cell mice

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 1, 2008, Pages 109-118

  Shet, Arun S ^a   Hoffmann, Thomas J ^a   Jirouskova, Marketa ^a   Janczak, Christin A ^a   Stevens, Jacqueline R M ^a   Adamson, Adewole ^a   Mohandas, Narla ^b   Manci, Elizabeth A ^c   Cynober, Therese ^d   Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Berkeley mouse model; Platelet size; Sickle cell

Indexed keywords

ANTIBODY; FIBRINOGEN; GLYCOCALICIN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; RNA; THIAZOLE ORANGE; THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; LIGHT SCATTERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SICKLE CELL; SPLEEN DISEASE; SPLENOMEGALY; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE STRUCTURE; THROMBOCYTE VOLUME; THROMBOCYTOPENIA;

ANEMIA, SICKLE CELL; ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FIBRINOGEN; MICE; MICE, MUTANT STRAINS; ORGAN SIZE; P-SELECTIN; PLATELET ACTIVATION; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; SPLEEN; THROMBOPOIETIN;

ANIMALIA; MUS;

EID: 44449170789     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.01.008     Document Type: Article

References (97)

1. Paszty C., et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278 (1997) 876-878
2. Pritchard Jr. K.A., et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am. J. Physiol. Lung. Cell. Mol. Physiol. 286 (2004) L705-L714
3. Kaul D.K., Liu X.D., Chang H.Y., Nagel R.L., and Fabry M.E. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J. Clin. Invest. 114 (2004) 1136-1145
4. Belcher J.D., et al. Transgenic sickle mice have vascular inflammation. Blood 101 (2003) 3953-3959
5. Manci E.A., Hillery C.A., Bodian C.A., Zhang Z.G., Lutty G.A., and Coller B.S. Pathology of "Berkeley" sickle cell mice: similarities and differences with human sickle cell disease. Blood 107 (2006) 1651-1658
6. Adamides S., Konstantopoulos K., Toumbis M., Douratsos D., Travlou A., and Kasfiki A. A study of beta-thromboglobulin and platelet factor-4 plasma levels in steady state sickle cell patients. Blut 61 (1990) 245-247
7. Buchanan G.R., and Holtkamp C.A. Platelet aggregation, malondialdehyde generation and production time in children with sickle cell anaemia. Thromb. Haemost. 46 (1981) 690-693
8. Browne P.V., Mosher D.F., Steinberg M.H., and Hebbel R.P. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am. J. Hematol. 51 (1996) 296-301
9. Haut M.J., Cowan D.H., and Harris J.W. Platelet function and survival in sickle cell disease. J. Lab. Clin. Med. 82 (1973) 44-53
10. Mehta P., and Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J. Pediatr. 96 (1980) 209-213
11. Stuart M.J., Stockman J.A., and Oski F.A. Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle-cell anemia. J. Pediatr. 85 (1974) 629-632
12. Westwick J., et al. Platelet activation during steady state sickle cell disease. J. Med. 14 (1983) 17-36
13. Wun T., Paglieroni T., Tablin F., Welborn J., Nelson K., and Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J. Lab. Clin. Med. 129 (1997) 507-516
14. Wun T., Cordoba M., Rangaswami A., Cheung A.W., and Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin. Lab. Haematol. 24 (2002) 81-88
15. Mehta P., and Mehta J. Circulating platelet aggregates in sickle cell disease patients with and without vaso-occlusion. Stroke 10 (1979) 464-466
16. Beurling-Harbury C., and Schade S.G. Platelet activation during pain crisis in sickle cell anemia patients. Am. J. Hematol. 31 (1989) 237-241
17. Francis R.B. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood. Coagul. Fibrinolysis. 2 (1991) 341-353
18. Tomer A., Harker L.A., Kasey S., and Eckman J.R. Thrombogenesis in sickle cell disease. J. Lab. Clin. Med. 137 (2001) 398-407
19. Stuart M.J., and Nagel R.L. Sickle-cell disease. Lancet 364 (2004) 1343-1360
20. Greenberg J., Ohene-Frempong K., Halus J., Way C., and Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J. Pediatr. 102 (1983) 781-784
21. Semple M.J., Al Hasani S.F., Kioy P., and Savidge G.F. A double-blind trial of ticlopidine in sickle cell disease. Thromb. Haemost. 51 (1984) 303-306
22. Cabannes R., Lonsdorfer J., Castaigne J.P., Ondo A., Plassard A., and Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents. Actions. Suppl. 15 (1984) 199-212
23. Zago M.A., Costa F.F., Ismael S.J., Tone L.G., and Bottura C. Treatment of sickle cell diseases with aspirin. Acta. Haematol. 72 (1984) 61-64
24. Chaplin Jr. H., Alkjaersig N., Fletcher A.P., Michael J.M., and Joist J.H. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb. Haemost. 43 (1980) 218-221
25. Stockman J.A., Nigro M.A., Mishkin M.M., and Oski F.A. Occlusion of large cerebral vessels in sickle-cell anemia. N. Engl. J. Med. 287 (1972) 846-849
26. Merkel K.H., Ginsberg P.L., Parker Jr. J.C., and Post M.J. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 9 (1978) 45-52
27. Rothman S.M., Fulling K.H., and Nelson J.S. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann. Neurol. 20 (1986) 684-690
28. Steen R.G., et al. Brain imaging findings in pediatric patients with sickle cell disease. Radiology 228 (2003) 216-225
29. Tuohy A.M., McKie V., Manci E.A., and Adams R.J. Internal carotid artery occlusion in a child with sickle cell disease: case report and immunohistochemical study. J. Pediatr. Hematol. Oncol. 19 (1997) 455-458
30. Paszty C., et al. Lethal alpha-thalassaemia created by gene targeting in mice and its genetic rescue. Nat. Genet. 11 (1995) 33-39
31. Ciavatta D.J., Ryan T.M., Farmer S.C., and Townes T.M. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9259-9263
32. Skow L.C., et al. A mouse model for beta-thalassemia. Cell 34 (1983) 1043-1052
33. Lengweiler S., et al. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem. Biophys. Res. Commun. 262 (1999) 167-173
34. Bergmeier W., Rackebrandt K., Schroder W., Zirngibl H., and Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood 95 (2000) 886-893
35. Moritz A., Fickenscher Y., Meyer K., Failing K., and Weiss D.J. Canine and feline hematology reference values for the ADVIA 120 hematology system. Vet. Clin. Pathol. 33 (2004) 32-38
36. Alugupalli K.R., Michelson A.D., Barnard M.R., and Leong J.M. Serial determinations of platelet counts in mice by flow cytometry. Thromb. Haemost. 86 (2001) 668-671
37. Holme S., Heaton A., Konchuba A., and Hartman P. Light scatter and total protein signal distribution of platelets by flow cytometry as parameters of size. J. Lab. Clin. Med. 112 (1988) 223-231
38. Holme S., Heaton A., Konchuba A., and Hartman P. Light scatter and total protein signal distribution of platelets by flow cytometry as parameters of size. J. Lab. Clin. Med. 112 (1988) 223-231
39. Schlenke P., et al. Evaluation of a flow cytometric method for simultaneous leukocyte phenotyping and quantification by fluorescent microspheres. Cytometry 33 (1998) 310-317
40. Tsuji T., Sakata T., Hamaguchi Y., Wang F., and Houwen B. New rapid flow cytometric method for the enumeration of nucleated red blood cells. Cytometry 37 (1999) 291-301
41. Kina T., et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109 (2000) 280-287
42. Lane P.A., et al. Functional asplenia in hemoglobin SC disease. Blood 85 (1995) 2238-2244
43. Ault K.A. Flow cytometric measurement of platelet function and reticulated platelets. Ann. N. Y. Acad. Sci. 677 (1993) 293-308
44. Matic G.B., Chapman E.S., Zaiss M., Rothe G., and Schmitz G. Whole blood analysis of reticulated platelets: improvements of detection and assay stability. Cytometry 34 (1998) 229-234
45. Baker G.R., Sullam P.M., and Levin J. A simple, fluorescent method to internally label platelets suitable for physiological measurements. Am. J. Hematol. 56 (1997) 17-25
46. Diehl K.H., et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21 (2001) 15-23
47. Heilmann E., et al. Biotinylated platelets: a new approach to the measurement of platelet life span. Br. J. Haematol. 85 (1993) 729-735
48. Berger G., Hartwell D.W., and Wagner D.D. P-Selectin and platelet clearance. Blood 92 (1998) 4446-4452
49. Faruqi T.R., Weiss E.J., Shapiro M.J., Huang W., and Coughlin S.R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J. Biol. Chem. 275 (2000) 19728-19734
50. McFarland J.G., Anderson A.J., and Slichter S.J. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br. J. Haematol. 73 (1989) 380-386
51. Brown A.K., Sleeper L.A., Miller S.T., Pegelow C.H., Gill F.M., and Waclawiw M.A. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative study of sickle cell disease. Arch. Pediatr. Adolesc. Med. 148 (1994) 796-804
52. Noronha J.F., Costa F.F., Saad S.T., Lorand-Metze I.G., and Grotto H.Z. Evaluation of reticulated platelets in patients with sickle cell diseases. Thromb. Res. (2007)
53. Kaushansky K. Lineage-specific hematopoietic growth factors. N. Engl. J. Med. 354 (2006) 2034-2045
54. Kuter D.J. New thrombopoietic growth factors. Blood 109 (2007) 4607-4616
55. Wang C., Smith B.R., Ault K.A., and Rinder H.M. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 42 (2002) 368-374
56. Garg S.K., Amorosi E.L., and Karpatkin S. Use of the megathrombocyte as an index of megakaryocyte number. N. Engl. J. Med. 284 (1971) 11-17
57. Tablin F., Castro M., and Leven R.M. Blood platelet formation in vitro. The role of the cytoskeleton in megakaryocyte fragmentation. J. Cell. Sci. 97 Pt 1 (1990) 59-70
58. Li J., and Kuter D.J. The end is just the beginning: megakaryocyte apoptosis and platelet release. Int. J. Hematol. 74 (2001) 365-374
59. Steinberg M.H., Kelton J.G., and Coller B.S. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N. Engl. J. Med. 317 (1987) 1037-1042
60. Haiden N., et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thromb. Haemost. 93 (2005) 118-123
61. Wun T., et al. Platelet activation in patients with sickle cell disease. Br. J. Haematol. 100 (1998) 741-749
62. Villagra J., Shiva S., Hunter L.A., Machado R.F., Gladwin M.T., and Kato G.J. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110 (2007) 2166-2172
63. Breimo E.S., and Osterud B. Studies of biological functions in blood cells from individuals with large platelets. Platelets 14 (2003) 413-419
64. Peters L.L., et al. Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol. Genomics. 11 (2002) 185-193
65. Freedman M.L., and Karpatkin S. Elevated platelet count and megathrombocyte number in sickle cell anemia. Blood 46 (1975) 579-582
66. Popescu E.R., and Martelo O.J. Megathrombocytes and sickle cell anemia. Blood 49 (1977) 490-491
67. Mohan J.S., Lip G.Y., Bareford D., and Blann A.D. Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship to genotype. Thromb. Res. (2005)
68. Inwald D.P., et al. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br. J. Haematol. 111 (2000) 474-481
69. Kenny M.W., George A.J., and Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J. Clin. Pathol. 33 (1980) 622-625
70. Lee S.P., Ataga K.I., Orringer E.P., Phillips D.R., and Parise L.V. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1626-1631
71. Raghavachari N., et al. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 115 (2007) 1551-1562
72. Gruppo R.A., Glueck H.I., Granger S.M., and Miller M.A. Platelet function in sickle cell anemia. Thromb. Res. 10 (1977) 235
73. Sarji K.E., Eurenius K., Fullwood C.O., Schraibman H.B., and Colwell J.A. Abnormalities of platelet aggregation in sickle cell anemia. Presence of a plasma factor inhibiting aggregation by ristocetin. Thromb. Res. 14 (1979) 283-297
74. Bernaudin F., et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J. Child. Neurol. 15 (2000) 333-343
75. Hayes R.J., Beckford M., Grandison Y., Mason K., Serjeant B.E., and Serjeant G.R. The haematology of steady state homozygous sickle cell disease: frequency distributions, variation with age and sex, longitudinal observations. Br. J. Haematol. 59 (1985) 369-382
76. Miller S.T., et al. Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med. 342 (2000) 83-89
77. Morris J., et al. The haematology of homozygous sickle cell disease after the age of 40 years. Br. J. Haematol. 77 (1991) 382-385
78. McKerrell T.D., Cohen H.W., and Billett H.H. The older sickle cell patient. Am. J. Hematol. 76 (2004) 101-106
79. Platt O.S., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330 (1994) 1639-1644
80. Sebastiani P., et al. A network model to predict the risk of death in sickle cell disease. Blood 110 (2007) 2727-2735
81. Turhan A., Weiss L.A., Mohandas N., Coller B.S., and Frenette P.S. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3047-3051
82. Smyth S.S., Reis E.D., Zhang W., Fallon J.T., Gordon R.E., and Coller B.S. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation 103 (2001) 2501-2507
83. Lee S.P., et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br. J. Haematol. 139 (2007) 612-620
84. de Caestecker M. Serotonin signaling in pulmonary hypertension. Circ. Res. 98 (2006) 1229-1231
85. Hoppe C. Defining stroke risk in children with sickle cell anaemia. Br. J. Haematol. 128 (2005) 751-766
86. Koshy M., Thomas C., and Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J. Assoc. Acad. Minor. Phys. 1 (1990) 71-78
87. Kirkham F.J. Therapy insight: stroke risk and its management in patients with sickle cell disease. Nat. Clin. Pract. Neurol. 3 (2007) 264-278
88. O'Malley T., Langhorne P., Elton R.A., and Stewart C. Platelet size in stroke patients. Stroke 26 (1995) 995-999
89. Martin J.F., Bath P.M., and Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991) 1409-1411
90. Greisenegger S., Endler G., Hsieh K., Tentschert S., Mannhalter C., and Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke 35 (2004) 1688-1691
91. Bath P., Algert C., Chapman N., and Neal B. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35 (2004) 622-626
92. Pizzulli L., Yang A., Martin J.F., and Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur. Heart. J. 19 (1998) 80-84
93. Huczek Z., et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 46 (2005) 284-290
94. Kirkham F.J., et al. Trials in sickle cell disease. Pediatr. Neurol. 34 (2006) 450-458
95. Dobson S.R., et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99 (2002) 3144-3150
96. Reiter C.D., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8 (2002) 1383-1389
97. Eberhardt R.T., et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am. J. Hematol. 74 (2003) 104-111